Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide

References

• WHO. Classification of tumours editorial board. Thoracic tumours: WHO classification of tumours. Vol. 5th edition. Lyon, France: International Agency for Research on Cancer: WHO; 2021.
   Google Scholar
• Atieh T, Huang CH. Treatment of advanced-stage large cell neuroendocrine cancer (LCNEC) of the lung: a tale of two diseases. Front Oncol. 2021;11:667468. doi:10.3389/fonc.2021.667468.
   PubMedGoogle Scholar
• Ferrara MG, Stefani A, Simbolo M, et al. Large cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities. Front Oncol. 2021;11:650293. doi:10.3389/fonc.2021.650293.
   PubMedGoogle Scholar
• Dam G, Grønbæk H, Sundlöv A, et al. Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Acta Oncol. 2023;62(5):431–437. doi:10.1080/0284186X.2023.2212411.
   PubMed Web of Science ®Google Scholar
• Al-Toubah T, Morse B, Strosberg J. Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Oncologist. 2020;25(1):e48–e52. doi:10.1634/theoncologist.2019-0361.
   PubMed Web of Science ®Google Scholar
• Chan DL, Bergsland EK, Chan JA, et al. Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: a multicenter retrospective review. Oncologist. 2021;26(11):950–955. doi:10.1002/onco.13923.
   PubMed Web of Science ®Google Scholar
• Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012;30(24):2963–2968. doi:10.1200/JCO.2011.40.3147.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhao Z, Wang J, et al. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis. Medicine. 2018;97(41):e12784. doi:10.1097/MD.0000000000012784.
   PubMed Web of Science ®Google Scholar
• Filosso PL, Guerrera F, Evangelista A, et al. Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European society for thoracic surgeons lung neuroendocrine tumours retrospective database. Eur J Cardiothorac Surg. 2017;52:339–345. doi:10.1097/MD.0000000000012784.
   PubMed Web of Science ®Google Scholar
• Soldath P, Binderup T, Carstensen F, et al. Long-term outcomes after video-assisted thoracoscopic surgery in pulmonary large-cell neuroendocrine carcinoma. Surgical Oncol. 2022;41:101728. doi:10.1097/MD.0000000000012784.
   PubMed Web of Science ®Google Scholar
• Le Treut J, Sault MC, Lena H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24(6):1548–1552. doi:10.1093/annonc/mdt009.
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Engel-Riedel W, Grohé C, et al. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Ann Oncol. 2017;28(8):1898–1902. doi:10.1093/annonc/mdx268.
   PubMed Web of Science ®Google Scholar
• Derks JL, Leblay N, Thunnissen E, et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res. 2018;24(1):33–42. doi:10.1158/1078-0432.CCR-17-1921.
   PubMed Web of Science ®Google Scholar
• Sun J-M, Ahn M-J, Ahn JS, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer. 2012;77(2):365–370. doi:10.1016/j.lungcan.2012.04.009.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Santos-Zabala ML, Iyriboz T, et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin Lung Cancer. 2016;17(5):e121–e129. doi:10.1016/j.cllc.2016.01.003.
   PubMed Web of Science ®Google Scholar
• Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8(7):980–984. doi:10.1097/JTO.0b013e31828f6989.
   PubMed Web of Science ®Google Scholar
• Alnahhas I, Alsawas M, Rayi A, et al. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020;2(1):vdaa082. doi:10.1093/noajnl/vdaa082.
   PubMedGoogle Scholar
• Campana D, Walter T, Pusceddu S, et al. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine. 2018;60(3):490–498. doi:10.1007/s12020-017-1474-3.
   PubMed Web of Science ®Google Scholar
• Cros J, Hentic O, Rebours V, et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(8):625–633. doi:10.1530/ERC-16-0117.
   PubMed Web of Science ®Google Scholar
• Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(9):759–767. doi:10.1530/ERC-16-0147.
   PubMed Web of Science ®Google Scholar